AAD 2025: Advancements in Dermatology
Paul Yamauchi, MD, PhD, discusses recent findings presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) on tildrakizumab’s efficacy for nail psoriasis, biological treatment patterns in moderate to severe psoriasis, ruxolitinib cream’s role in reducing additional medication use in atopic dermatitis, comparative infection risks between Janus kinase and cytokine inhibitors, and the evolution toward personalized dermatological treatment approaches that balance efficacy with safety considerations.
Episodes
March 31st 2025EP. 1: Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.
April 14th 2025EP. 3: Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.
April 21st 2025EP. 4: Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis (AD) significantly reduced patients’ reliance on other topical treatments, oral corticosteroids, and biologics in both biologic-experienced (n = 125) and biologic-naive (n = 431) populations, suggesting this Janus kinase (JAK) inhibitor may serve as an effective steroid-sparing agent with potential for long-term disease management across different patient subgroups.
